Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027066 (
myoclonus
)
4,275
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Variants in the neuronal sodium channel gene
SCN8A
have been implicated in several neurological disorders. Early infantile epileptic encephalopathy type 13 results from de novo gain-of-function mutations that alter the biophysical properties of the channel. Complete loss-of-function variants of
SCN8A
have been identified in cases of isolated intellectual disability. We now report a novel heterozygous
SCN8A
variant, p.Pro1719Arg, in a small pedigree with five family members affected with autosomal dominant upper limb isolated
myoclonus
without seizures or cognitive impairment. Functional analysis of the p.Pro1719Arg variant in transfected neuron-derived cells demonstrated greatly reduced Na
v
1.6 channel activity without altered gating properties. Hypomorphic alleles of Scn8a in the mouse are known to result in similar movement disorders. This study expands the phenotypic and functional spectrum of
SCN8A
variants to include inherited nonepileptic isolated
myoclonus
.
SCN8A
can be considered as a candidate gene for isolated movement disorders without seizures.
...
PMID:Partial loss-of-function of sodium channel SCN8A in familial isolated myoclonus. 2972 66
Pathogenic variants in
SCN8A
have originally been described in patients with developmental and epileptic encephalopathy (DEE). However, recent studies have shown that
SCN8A
variants can be associated with a broader phenotypic spectrum, including the following: (1) Patients with early onset, severe DEE, developing severe cognitive and motor regression, pyramidal/extrapyramidal signs, and cortical blindness. Severe
SCN8A
-DEE is characterized by intractable seizures beginning in the first months of life. The seizures are often prolonged focal hypomotor and occur in clusters, with prominent vegetative symptoms (apnea, cyanosis, mydriasis), evolving to clonic or bilateral tonic-clonic manifestations. Spasm-like episodes, cortical
myoclonus
, and recurrent episodes of status epilepticus are also common. Electroencephalograms (EEGs) show progressive background deterioration and multifocal abnormalities, predominant in the posterior regions. (2) Sporadic and familial patients with mild-to-moderate intellectual disability, discrete neurological signs, and treatable epilepsy. EEG is abnormal in half of the cases, showing multifocal or diffuse epileptiform abnormalities. (3) Familial cases with benign infantile seizures, sometimes associated with paroxysmal dyskinesia later in life, with no other neurological deficits, normal cognition, and usually normal interictal EEG. (4) Patients without epilepsy but with cognitive and/or behavioral disturbances, or with movement disorders. Extrapyramidal features, such as dyskinesia, ataxia, and choreoathetosis are common in all groups. Early death has been reported in about 5% of the patients, most often in the subgroup of severe DEE. Premature death occurs during early childhood and often for causes other than sudden unexpected death in epilepsy. All epilepsy subgroups exhibit better seizure control with sodium channel blockers, usually at supratherapeutic doses in the severe cases. In severe
SCN8A
-DEE, ketogenic diet often has a good effect, whereas levetiracetam has a negative effect, if any. The familial
SCN8A
-related epilepsies show an autosomal dominant pattern of inheritance, whereas the vast majority of
SCN8A
-DEEs occur de novo.
...
PMID:Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes. 3190 24